STOCK TITAN

Andrew Callos 10b5-1 sales reported for CYTK (NASDAQ: CYTK)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Andrew Callos reported multiple planned sales of Common Stock under a Rule 10b5-1 plan. The filing lists individual dispositions dated between 12/29/2025 and 03/09/2026, including transactions of 15,000 shares on 01/05/2026 and 15,000 shares on 02/05/2026, with listed proceeds for each trade. The transactions are described as 10b5-1 sales.

Positive

  • None.

Negative

  • None.

Insights

Insider executed scheduled 10b5-1 sales across multiple dates; pattern consistent with pre-arranged liquidity.

Andrew Callos reports a sequence of dispositions labeled as 10b5-1 Sales, with multiple entries of $928,062.00 for 03/05/2026 and similar amounts on other dates. The filing lists exact share counts and gross proceeds by date.

These entries reflect pre-arranged trading activity; cash‑flow treatment to the selling holder is clear from the schedule, and timing follows the plan dates shown in the excerpt.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did the Form 144 for CYTK disclose about insider sales?

The Form 144 discloses multiple planned dispositions by Andrew Callos under a Rule 10b5-1 plan. The filing lists individual share counts and gross proceeds for trades between 12/29/2025 and 03/09/2026, including several 15,000-share transactions.

How many shares did Andrew Callos sell on key dates in the filing?

The filing shows several specific trades of 15,000 shares on dates including 01/05/2026 and 02/05/2026. It also lists other quantities such as 2,582 and 1,809 shares on earlier and later dates in the excerpt.

Were the sales described as part of a trading plan in the Form 144?

Yes. The dispositions are labeled throughout the excerpt as 10b5-1 Sales, indicating they were executed under a pre-arranged Rule 10b5-1 plan rather than ad hoc open‑market timing decisions.

What proceeds are listed for the reported transactions in the filing?

The excerpt lists gross proceeds for individual trades, for example $928,062.00 for a 15,000-share sale on 03/05/2026 and $904,165.50 for a 15,000-share sale on 01/05/2026, with other per‑trade dollar amounts shown.
Cytokinetics Inc

NASDAQ:CYTK

View CYTK Stock Overview

CYTK Rankings

CYTK Latest News

CYTK Latest SEC Filings

CYTK Stock Data

7.66B
120.48M
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO